Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.74 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604295 | 0.98 | ELANE (0.73) | ELANEHTR2AHTR2CSLC6A4CTSK | |
| SCHEMBL1603837 | 0.96 | ELANE (0.76) | ELANECTSK | |
| SCHEMBL14922185 | 0.90 | ELANE (0.81) | ELANE | |
| SCHEMBL14922184 | 0.90 | ELANE (0.80) | ELANE | |
| SCHEMBL1604898 | 0.89 | ELANE (0.78) | ELANE | |
| SCHEMBL1604972 | 0.89 | ELANE (0.73) | ELANE | |
| SCHEMBL1604290 | 0.88 | ELANE (0.77) | ELANE | |
| Bromide SCHEMBL1603849 | 0.88 | ELANE (0.77) | ELANE | |
| SCHEMBL1604172 | 0.88 | ELANE (0.77) | ELANECTSK | |
| SCHEMBL27872087 | 0.88 | ELANE (0.82) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082155-A1 | Novel 2-Pyridone Compounds | SERPINB1, ELANE, EPX | ELANE 2/4885HTR2A 3242/4885HTR2C 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.